entertainment -WSS

entertainment

author：fashion 2025-09-01 15:17:54 - browse：36575

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

WSS

Chemotherapy before breast cancer surgery might fuel metastasis

PBM executives asked to testify by House panel

FDA panel issues narrow recommendation for Covid vaccine booster doses

Class action alleges UnitedHealth concealed DOJ probe

Class action alleges UnitedHealth concealed DOJ probe

South Korea throws huge K

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

HHS's proposed rule does nothing to address the climate crisis

Apple is now the first public company to be valued at $3 trillion

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

BioMarin wins approval for gene therapy to treat hemophilia A

Police still searching for prisoner who escaped from NYC hospital

Affirmative action in medical school literally saved lives

NIH trials fail to test meaningful long Covid therapies, experts say

Duchenne breakthrough therapy leaves behind pioneering families

Wegovy’s successful heart trial raises vital question about weight loss

leisure time

Wegovy’s successful heart trial raises vital question about weight loss

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

As health system earnings go up, health insurance stocks go down

Can gargling with Listerine treat gonorrhea of the mouth?

AI for drug discovery: Experts on separating hype from reality

Empower primary care with adequate payments and technology

focus

explore

hotspot

hotspot